
-
Intellia Therapeutics NasdaqGM:NTLA Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Location: 40 Erie Street, Cambridge, MA, 02139, United States | Website: https://www.intelliatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
387.2M
Cash
503.7M
Avg Qtr Burn
-94.29M
Short % of Float
31.18%
Insider Ownership
4.96%
Institutional Own.
96.90%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
nexiguran ziclumeran (nex-z) (NTLA-2001) Details ATTR amyloidosis with polyneuropathy (ATTRv-PN) | Phase 3 Data readout | |
NTLA-2002 (KLKB1 Inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease | Phase 1/2 Data readout | |
NTLA-3001 Details Alpha-1 Antitrypsin Deficiency, Lung disease | Phase 1/2 Update | |
nexiguran ziclumeran (nex-z) (NTLA-2001) Details Transthyretin Amyloid Cardiomyopathy | Phase 1 Update | |
NTLA-5001 Details Acute myeloid leukemia | Failed Discontinued | |
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease | Failed Discontinued |